April 18, 2025 a 03:31 pm
BDX: Fundamental Ratio Analysis - Becton, Dickinson and Company
Becton, Dickinson and Company is a prominent player in the healthcare sector, known for its wide range of medical supplies, devices, and diagnostic products. The company's diversified product lines and global reach position it well for steady growth. However, investors should be mindful of the inherent risks in the healthcare industry.
Fundamental Rating
The fundamental analysis of BDX suggests a balanced financial health with an overall score of 3. The following table illustrates the various aspects evaluated:
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 3 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 2 |
Historical Rating
The historical ratings provide insight into how the company's fundamentals have evolved:
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-04-17 | 3 | 5 | 3 | 4 | 1 | 1 | 2 |
| Previous Date | 0 | 5 | 3 | 4 | 1 | 1 | 2 |
Analyst Price Targets
Analyst estimates indicate potential price movements with a consensus rating of "Buy":
| High | Low | Median | Consensus |
|---|---|---|---|
| 312 | 255 | 280 | 283.27 |
Analyst Sentiment
The current sentiment among analysts is largely positive, with the following distribution:
| Recommendation | Number | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 19 | |
| Hold | 11 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Becton, Dickinson and Company exhibits steady performance with potential for growth in the medical instruments sector. The overall fundamental score of 3 suggests moderate financial health. Analyst recommendations are mostly positive, indicating confidence in the stock's future price trajectory. However, challenges like industry regulations and market competition remain. Investors should weigh these prospects carefully when considering BDX in their portfolio.